Drug class in one race
Glucocorticoid receptor drugs for Chronic Kidney Disease
2 tracked Glucocorticoid receptor drugs in the Chronic Kidney Disease race. The class explanation lives on the Glucocorticoid receptor page; the full indication pipeline across every mechanism is on the Chronic Kidney Disease page.
1 approved / phase 41 preclinical / unstaged
Head-to-head evidence: Budesonide (targeted-release) vs Relacorilant (Lifyorli)